S508
Methods: An electronic survey system based on the Redcap database
Figure 1.  Mean total costs (with standard error) per year for the total cohort
and per era.
Mean and median cumulative total costs (CTC) are displayed in
Table 1. After 2 years from diagnosis and onwards, mean CTC dif-
fered significantly between eras. Post-hoc analysis showed significant
differences between the first and the other two eras, but not between
the second and third era (Table 1). Mean costs per year (calculated
over 5-year follow-up) were €2538, €3889, and €4838, respectively,
for the consecutive eras.
Conclusions: In this population-based study, direct healthcare costs
after the first year were higher for each consecutive era, leading to an
increase in total direct costs of CD over time. Future studies should
investigate whether this increase is compensated by a decrease in
indirect costs (e.g. decreased work disability).
P785
Designing the first pan-European paediatric IBD
database to allow the study of incidence and
prevalence of UC, CD, and their rare and severe
complications
P. Kemos1*, M. Aardoom2, F. Ruemmele3, L. de Ridder2,
N. Croft1,
on behalf of the PIBD SETQuality consortium and PIBDnet
1
Centre for Immunobiology, Blizard Institute, Barts and the
London School of Medicine, Queen Mary University of London,
Paediatric Gastroenterology, London, UK, 2Erasmus MC, Sophia
Children's Hospital, Paediatric Gastroenterology, Rotterdam, The
Netherlands, 3Université Paris Descartes, Sorbonne Paris Cité,
APHP, Hopital Necker Enfants Malades, Department of Paediatric
Gastroenterology, Paris, France
Background: The incidence and prevalence of paediatric-onset
inflammatory bowel disease (PIBD) and related complications is cur-
rently unknown or unclear in several European and non-European
countries. We designed an electronic survey system, which allows us
to collect PIBD denominator data, annually. With this study we aim
to determine the incidence and prevalence of PIBD and its rare and
severe disease or treatment-related complications and reveal import-
ant differences between regions, populations and other variables as
well as trends over time.
Poster presentations
was designed to capture the referral and patient population of PIBD
experts in 23 countries. This is part of the study examining rare
complications of PIBD within the H2020 funded PIBD SETQuality.
PIBD experts are invited to complete an annual survey that collects
data regarding the location and type of clinical service, and number
of new and current cases of PIBD. It also identifies from where their
patients are mainly referred (regional coverage). A key element is the
use of the Nomenclature of Territorial Units for Statistics (NUTS3)
as defined by Eurostat.1 This structure allows us to combine the col-
lected regional PIBD data with the 4600 validated datasets that are
Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/12/supplement_1/S508/4808251 by guest on 13 April 2019
available in the Eurostat databases. In order to validate the quality
of collected data, the source of information for entered data in each
survey is also captured.
Results: Within one year we have gathered responses from 62
paediatric gastroenterologists in different regions of 16 European
countries and Israel. Thus we have reviewed reports from 5 coun-
tries with the population covered reaching 16.8 million children
and estimated incidence and prevalence through this system. For
the UK, the Netherlands (NL), Sweden (SE), Italy (IT) and Israel
(IS), the coverage of the paediatric population reaches 49%, 77%,
22%, 35%, and 57%, respectively. Preliminary results are pre-
sented in table.
Country Incidence per 105 Prevalence per 105
(95% CI) (95% CI)
UK 6.5 (5.9–7.4) 28.9 (27.6–30.1)
NL 5.6 (4.8–6.5) 28.3 (26.5–30.2)
IS 6.9 (5.7–8.2) 27.3 (25–30)
IT 1.9 (1.5–2.3) 16.7 (15.5–18)
SE 7.6 (5.4–10.5) 48.8 (42.8–55.3)
Conclusions: This has shown our ability to obtain incidence and
prevalence data of PIBD, compatible with previous data, through
studying a very large Pan-European referral population allowing dir-
ect comparison between different countries and regions. These data
will allow us to feedback precise figures to our responders in regard
to their local populations and further examine reasons for reported
differences in disease incidence and prevalence between countries
and regions. *Funding source no.: 668023.
Reference
1. European Commission, Eurostat, NUTS. Nomenclature of ter-
ritorial units for statistics. Overview. 2017. http://ec.europa.eu/
eurostat/web/nuts, accessed on November 1, 2017.
P786
The use and escalation of treatments in patients
with inflammatory bowel disease; a 10 years
follow-up of a Danish population-based inception
cohort
B. Lo1*, I. Vind1, F. Bendtsen1, M. Vester-Andersen1,2, J. Burisch1
1
Copenhagen University Hospital Hvidovre, The Gastro Unit,
Medical Division, Hvidovre, Denmark, 2Zealand University
Hospital, Medical Department, Køge, Denmark
Background: The long-term treatment strategies and change
between medications in Inflammatory bowel disease (IBD) in the age
of biologics has not been well described. We aimed to characterise
the treatment strategies in IBD in a well-defined population-based